A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

• Status: Unknown status
• Trial end date: 2016-12-01

Summary

SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.

From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms:

• Targeted therapy based on the molecular profile

• Conventional therapy based on investigator's choice.

A cross-over is proposed at disease progression.

• Phase: Phase 2

Details

• Lead Sponsor: Institut Curie
• Treatments: Dasatinib; Erlotinib Hydrochloride; Everolimus; Imatinib Mesylate; Lapatinib; Letrozole; Sirolimus; Sorafenib; Tamoxifen; Trastuzumab; Vemurafenib